Oligodendroglia

Download PDF

Recent Publications on Oligodendroglia:
Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination. Oligodendrogliopathy, microglial infiltration, and lack of remyelination...	11th July, 2008	Department of Neuroscience and Cell Biology, Robert Wood Johnson Medical	J Neurosci. 2008 Jun 11;28(24):6118-27. DOI Direct Link
Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. The immature brains of newborns often respond differently from the brains...	9th July, 2008	Division of Developmental Biology and Division of Neurology, Cincinnati	Am J Pathol. 2008 Jun;172(6):1704-16. Epub 2008 May 8. DOI Direct Link
Yin Yang 1 Expression in the Adult Rodent Brain. Yin Yang 1 (YY1) is a ubiquitous transcription factor belonging to...	28th June, 2008	Department of Molecular and Cellular Neurobiology, Nencki Institute of	Neurochem Res. 2008 Jun 27;. DOI Direct Link
Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. OBJECTIVE: To investigate the therapeutic potential of mesenchymal stromal...	27th June, 2008	Department of Neurology and Agnes-Ginges Center for Neurogenetics,	Arch Neurol. 2008 Jun;65(6):753-61. DOI Direct Link
Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. Reactive microglia and astrocytes are present in lesions of white matter...	20th June, 2008	Department of Neurology and the F. M. Kirby Neurobiology Center,	J Neurosci. 2008 May 14;28(20):5321-30. DOI Direct Link
→View more research publications.

Oligodendroglia Clinical Trials:
Oligodendrocyte Progenitor Cell Culture From Human Brain	Demyelinating Diseases
The Classification and Cause of Leukodystrophies of Unknown Cause	Lysosomal Storage Disease
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients	Multiple Sclerosis

Oligodendroglia Patents:
US Patent No.	Title
6790657	Lentivirus vector system
7041507	Transdiffentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
7067254	Diagnosis and treatment of inflammation and hyperactive immune conditions
7074911	Endogenous granzyme B in non-immune cells
7098027	Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Oligodendroglia scientists - we have details of around 628 individuals working on Oligodendroglia .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.